source
- Novo Nordisk CFO describes roller-coaster growth and stays optimistic about CagriSema after Q2 earningsNovo Nordisk CFO Karsten Munk Knudsen talked to Fierce after the company released its second-quarter earnings, reflecting on his nine-year tenure and the firm’s volatile performance. He recalled a…
- Only one third of US prostate cancer patients received pre-biopsy MRI in 2022, far below Western normsMRI is considered the standard pre-biopsy imaging tool for prostate cancer in most western nations, yet a new analysis shows that only about a third of US cases used it in 2022. In the United Stat…